DexCom Stock Up Following Strong Preliminary Q4 Results & 2025 Outlook
DexCom, Inc. DXCM reported strong preliminary results for the fourth quarter and full-year 2024. In response, the company’s stock jumped 2.7% on Jan. 13. The company is scheduled to release its fourth-quarter results on Feb.
DexCom Inc. stock underperforms Tuesday when compared to competitors
DexCom Inc. closed $62.83 below its 52-week high ($142.00), which the company reached on March 26th.
Why DexCom Inc (DXCM) Stock is Currently 1.55% Above from Its 20-Day SMA?
On Monday, DexCom Inc (DXCM) stock saw a decline, ending the day at $79.88 which represents a decrease of $-1.19 or -1.47% from the prior close of $81.07. The stock opened at $81.95 and touched a low of $79.64 during the day, reaching a high of $82.66. The volume of shares traded was 3.44 million falling short of the average volume of 3.99 million.
DexCom Q4 Preliminary Revenue Improves; Pre-Market Stock Up
DexCom, Inc. (DXCM), a maker of continuous glucose monitoring systems for diabetes management, on Monday reported a rise in
DexCom Inc. stock outperforms competitors on strong trading day
Shares of DexCom Inc. DXCM rallied 2.67% to $79.84 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.16% to 5,836.22 and the Dow Jones Industrial Average DJIA rising 0.
DexCom stock rises on 2025 outlook
DexCom (NASDAQ:DXCM) shares popped 6% premarket on Monday after the company set its financial forecast for 2025, projecting adjusted gross profit margin of around 64% – 65% on revenue of $4.60B ($4.60B estimate).
Hosted on MSN11h
JP Morgan 2025: Dexcom shares up 5% after 2025 outlook forecasts $4.6bn in revenue
Buoyed by the recent launch of Stelo and further upcoming CGM launches, Dexcom is anticipating a 14% growth in 2025 over 2024 ...
Dexcom’s Strong Financial Performance and Growth Prospects Earns Buy Rating from Analyst
In a report released yesterday, William Plovanic from Canaccord Genuity maintained a Buy rating on Dexcom (DXCM – Research Report), with a ...
FierceBiotech15h
JPM25: Dexcom predicts 2025 growth, with Stelo pushing portfolio updates
After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have ...
bovnews1d
The DXCM Stock Mystery: Why Did DXCM Plunge Today?
On Friday, DexCom Inc (DXCM) stock saw a decline, ending the day at $77.76 which represents a decrease of $-2.33 or -2.91% from the prior close of $80.09. The stock opened at $79.5 and touched a low ...
Dexcom’s Strong Sales Growth and Strategic Advances Support Buy Rating
Matthew Taylor, an analyst from Jefferies, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target remains ...
24/7 Wall St3d
Billionaire Chase Coleman III Completely Sells Out of DexCom and Gambles the Proceeds on This Stock
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...
Decoding DexCom's Options Activity: What's the Big Picture?
Today, Benzinga 's options scanner spotted 11 uncommon options trades for DexCom. This isn't normal. The overall sentiment of ...
drugdeliverybusiness1d
Dexcom expects sales to grow 14% in 2025
Dexcom (Nasdaq:DXCM) today announced preliminary financial results with projections for significant sales growth in 2025.
Dexcom forecasts 2025 revenue largely in-line with expectations
Dexcom forecast total annual revenue largely in line with Wall Street expectations on Monday, on bets there will be strong demand for its continuous glucose monitors for diabetes patients, sending the ...
TD Cowen Sticks to Its Buy Rating for Dexcom (DXCM)
TD Cowen analyst Josh Jennings reiterated a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The ...